STOCK TITAN

[Form 4] Insulet Corporation Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Benjamin Eric, Executive Vice President and Chief Product Experience Officer at Insulet Corporation (PODD), reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at a price of $332.23 per share. Following the transaction, he beneficially owns 16,736 shares. The Form 4 indicates the sale was made pursuant to an existing Rule 10b5-1 trading plan. The filing also notes that 93 shares were acquired through the company Employee Stock Purchase Plan since his last Form 4. The document is a routine Section 16 disclosure of an insider sale under a pre-established plan and does not disclose additional transactions, derivatives, or other compensatory details.

Benjamin Eric, Vice President Esecutivo e Chief Product Experience Officer di Insulet Corporation (PODD), ha venduto 4.263 azioni del capitale sociale di Insulet il 21/08/2025 a un prezzo di $332,23 per azione. Dopo l'operazione detiene beneficiariamente 16.736 azioni. Il Modulo 4 indica che la vendita è avvenuta in base a un piano di negoziazione Rule 10b5-1 già esistente. La comunicazione segnala inoltre che sono state acquisite 93 azioni tramite il piano di acquisto azionario per i dipendenti dell'azienda dall'ultimo Modulo 4. Il documento rappresenta una normale comunicazione ai sensi della Sezione 16 relativa a una vendita di un insider prevista da un piano preesistente e non riporta transazioni aggiuntive, derivati o dettagli compensativi ulteriori.

Benjamin Eric, Vicepresidente Ejecutivo y Chief Product Experience Officer de Insulet Corporation (PODD), informó la venta de 4.263 acciones de acciones ordinarias de Insulet el 21/08/2025 a un precio de $332,23 por acción. Tras la operación, posee beneficiosamente 16.736 acciones. El Formulario 4 indica que la venta se realizó conforme a un plan de negociación Rule 10b5-1 ya existente. La presentación también señala que se adquirieron 93 acciones a través del Plan de Compra de Acciones para Empleados de la compañía desde su último Formulario 4. El documento es una divulgación rutinaria conforme a la Sección 16 sobre una venta por parte de un insider bajo un plan preestablecido y no detalla transacciones adicionales, derivados u otros aspectos compensatorios.

Benjamin Eric, Insulet Corporation(PODD)의 전무 겸 최고 제품 경험 책임자는 2025-08-21에 Insulet 보통주 4,263주를 주당 $332.23에 매도했다고 보고했습니다. 거래 후 그는 16,736주를 실질적으로 보유하고 있습니다. 양식 4에는 이번 매도가 기존의 Rule 10b5-1 거래 계획에 따라 이루어졌다고 기재되어 있습니다. 제출서에는 또한 지난 양식 4 이후 회사 직원 주식매수계획을 통해 93주를 취득했다는 내용도 포함되어 있습니다. 이 문서는 사전에 설정된 계획에 따른 내부자 매도에 관한 섹션 16의 통상적인 공시이며 추가 거래, 파생상품 또는 기타 보상 관련 세부사항은 기재되어 있지 않습니다.

Benjamin Eric, Vice‑Président Exécutif et Chief Product Experience Officer d'Insulet Corporation (PODD), a déclaré la vente de 4 263 actions ordinaires d'Insulet le 21/08/2025 au prix de 332,23 $ par action. À la suite de la transaction, il possède à titre bénéficiaire 16 736 actions. Le formulaire 4 indique que la vente a été réalisée conformément à un plan de négociation Rule 10b5-1 existant. Le dépôt précise également que 93 actions ont été acquises via le Plan d'Achat d'Actions pour les Employés de la société depuis son dernier formulaire 4. Le document constitue une divulgation routinière au titre de la Section 16 concernant une vente d'initié dans le cadre d'un plan préétabli et ne révèle pas d'autres transactions, produits dérivés ou éléments de rémunération supplémentaires.

Benjamin Eric, Executive Vice President und Chief Product Experience Officer bei Insulet Corporation (PODD), meldete den Verkauf von 4.263 Aktien der Insulet-Stammaktien am 21.08.2025 zu einem Preis von $332,23 je Aktie. Nach der Transaktion besitzt er wirtschaftlich 16.736 Aktien. Das Formular 4 gibt an, dass der Verkauf gemäß eines bereits bestehenden Rule 10b5-1 Trading Plans erfolgte. Die Einreichung vermerkt außerdem, dass seit seinem letzten Formular 4 93 Aktien über den Employee Stock Purchase Plan des Unternehmens erworben wurden. Das Dokument stellt eine routinemäßige Offenlegung nach Section 16 über einen Insiderverkauf im Rahmen eines vorab festgelegten Plans dar und enthält keine Angaben zu weiteren Transaktionen, Derivaten oder sonstigen vergütungsbezogenen Details.

Positive
  • Trade executed under a Rule 10b5-1 plan, which indicates the sale followed a pre-established trading program
  • Reporting shows continued beneficial ownership of 16,736 shares after the sale
Negative
  • Insider sold 4,263 shares, representing a reduction in executive shareholding
  • Filing does not disclose the size of the overall insider holding as a percentage of outstanding shares, limiting context

Insights

TL;DR: Routine disposition under a Rule 10b5-1 plan reduces insider holdings but signals adherence to pre-approved trading procedures.

The Form 4 documents a sale of 4,263 shares by an executive made under a 10b5-1 plan, which generally limits the risk of opportunistic trading allegations by showing trades followed a pre-set schedule. The filing confirms post-sale beneficial ownership of 16,736 shares and notes 93 shares added via the ESPP. From a governance perspective, this is a standard disclosure that demonstrates compliance with insider trading policies but represents a modest reduction in insider ownership that investors may track over time.

TL;DR: Single insider sale disclosed; transaction size appears routine and accompanied by 10b5-1 protection.

The sale price reported at $332.23 per share for 4,263 shares was executed on 08/21/2025 under a Rule 10b5-1 plan. The disclosure does not indicate any derivative transactions or additional disposals. The incremental acquisition of 93 ESPP shares since the last filing is immaterial relative to total ownership. This Form 4 is informational for monitoring insider ownership trends but does not, by itself, suggest material change in company control or immediate financial impact.

Benjamin Eric, Vice President Esecutivo e Chief Product Experience Officer di Insulet Corporation (PODD), ha venduto 4.263 azioni del capitale sociale di Insulet il 21/08/2025 a un prezzo di $332,23 per azione. Dopo l'operazione detiene beneficiariamente 16.736 azioni. Il Modulo 4 indica che la vendita è avvenuta in base a un piano di negoziazione Rule 10b5-1 già esistente. La comunicazione segnala inoltre che sono state acquisite 93 azioni tramite il piano di acquisto azionario per i dipendenti dell'azienda dall'ultimo Modulo 4. Il documento rappresenta una normale comunicazione ai sensi della Sezione 16 relativa a una vendita di un insider prevista da un piano preesistente e non riporta transazioni aggiuntive, derivati o dettagli compensativi ulteriori.

Benjamin Eric, Vicepresidente Ejecutivo y Chief Product Experience Officer de Insulet Corporation (PODD), informó la venta de 4.263 acciones de acciones ordinarias de Insulet el 21/08/2025 a un precio de $332,23 por acción. Tras la operación, posee beneficiosamente 16.736 acciones. El Formulario 4 indica que la venta se realizó conforme a un plan de negociación Rule 10b5-1 ya existente. La presentación también señala que se adquirieron 93 acciones a través del Plan de Compra de Acciones para Empleados de la compañía desde su último Formulario 4. El documento es una divulgación rutinaria conforme a la Sección 16 sobre una venta por parte de un insider bajo un plan preestablecido y no detalla transacciones adicionales, derivados u otros aspectos compensatorios.

Benjamin Eric, Insulet Corporation(PODD)의 전무 겸 최고 제품 경험 책임자는 2025-08-21에 Insulet 보통주 4,263주를 주당 $332.23에 매도했다고 보고했습니다. 거래 후 그는 16,736주를 실질적으로 보유하고 있습니다. 양식 4에는 이번 매도가 기존의 Rule 10b5-1 거래 계획에 따라 이루어졌다고 기재되어 있습니다. 제출서에는 또한 지난 양식 4 이후 회사 직원 주식매수계획을 통해 93주를 취득했다는 내용도 포함되어 있습니다. 이 문서는 사전에 설정된 계획에 따른 내부자 매도에 관한 섹션 16의 통상적인 공시이며 추가 거래, 파생상품 또는 기타 보상 관련 세부사항은 기재되어 있지 않습니다.

Benjamin Eric, Vice‑Président Exécutif et Chief Product Experience Officer d'Insulet Corporation (PODD), a déclaré la vente de 4 263 actions ordinaires d'Insulet le 21/08/2025 au prix de 332,23 $ par action. À la suite de la transaction, il possède à titre bénéficiaire 16 736 actions. Le formulaire 4 indique que la vente a été réalisée conformément à un plan de négociation Rule 10b5-1 existant. Le dépôt précise également que 93 actions ont été acquises via le Plan d'Achat d'Actions pour les Employés de la société depuis son dernier formulaire 4. Le document constitue une divulgation routinière au titre de la Section 16 concernant une vente d'initié dans le cadre d'un plan préétabli et ne révèle pas d'autres transactions, produits dérivés ou éléments de rémunération supplémentaires.

Benjamin Eric, Executive Vice President und Chief Product Experience Officer bei Insulet Corporation (PODD), meldete den Verkauf von 4.263 Aktien der Insulet-Stammaktien am 21.08.2025 zu einem Preis von $332,23 je Aktie. Nach der Transaktion besitzt er wirtschaftlich 16.736 Aktien. Das Formular 4 gibt an, dass der Verkauf gemäß eines bereits bestehenden Rule 10b5-1 Trading Plans erfolgte. Die Einreichung vermerkt außerdem, dass seit seinem letzten Formular 4 93 Aktien über den Employee Stock Purchase Plan des Unternehmens erworben wurden. Das Dokument stellt eine routinemäßige Offenlegung nach Section 16 über einen Insiderverkauf im Rahmen eines vorab festgelegten Plans dar und enthält keine Angaben zu weiteren Transaktionen, Derivaten oder sonstigen vergütungsbezogenen Details.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Benjamin Eric

(Last) (First) (Middle)
C/O INSULET CORPORATION
100 NAGOG PARK

(Street)
ACTON MA 01720

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INSULET CORP [ PODD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CPXO
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 S 4,263(1) D $332.23 16,736(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 was effected pursuant to an existing Rule 10b5-1 trading plan.
2. Includes 93 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing.
/s/ John W. Kapples, attorney-in-fact 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin Eric (PODD) report on Form 4?

He reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at $332.23 per share under a Rule 10b5-1 trading plan.

How many Insulet shares does the reporting person own after the transaction?

The Form 4 shows beneficial ownership of 16,736 shares following the reported sale.

Was the sale part of a pre-arranged trading plan?

Yes. The filing explicitly states the transaction was effected pursuant to an existing Rule 10b5-1 trading plan.

Did the report include any ESPP activity?

Yes. The filing notes that 93 shares were acquired under the Insulet Employee Stock Purchase Plan since the last Form 4 filing.

Were any derivative securities reported on this Form 4?

No. The Form 4 contains no entries in Table II for derivative securities.
Insulet Corp

NASDAQ:PODD

PODD Rankings

PODD Latest News

PODD Latest SEC Filings

PODD Stock Data

23.44B
70.12M
0.28%
101.73%
2.49%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ACTON